Tumor-associated B cells have even been proposed to promote resistance to BRAF and MEK inhibitors in melanoma through secretion of IGF-1 and clinical trials evaluating therapeutic B cell depletion in this context are underway (NCT01376713) [22]. This evidence concerns the gene BRAF and neoplasm.